新华制药
(000756)
| 流通市值：68.28亿 | | | 总市值：95.60亿 |
| 流通股本：4.93亿 | | | 总股本：6.90亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,429,825,335.81 | 8,466,309,803.08 | 6,734,166,240.75 | 4,732,481,467.24 |
| 营业收入 | 2,429,825,335.81 | 8,466,309,803.08 | 6,734,166,240.75 | 4,732,481,467.24 |
| 二、营业总成本 | 2,299,988,387.7 | 7,940,307,572.72 | 6,337,089,365.67 | 4,414,193,942.13 |
| 营业成本 | 1,974,290,313.61 | 6,424,760,721.71 | 5,151,913,375.72 | 3,547,931,805.24 |
| 税金及附加 | 17,878,928.9 | 68,412,881.15 | 51,662,674.6 | 36,899,978.55 |
| 销售费用 | 99,952,491.15 | 584,739,997.94 | 504,223,794.96 | 403,565,129.41 |
| 管理费用 | 94,042,826.77 | 437,070,533.59 | 292,405,195.99 | 181,073,486.83 |
| 研发费用 | 109,788,595.18 | 413,182,811.71 | 326,669,940.69 | 243,105,634.2 |
| 财务费用 | 4,035,232.09 | 12,140,626.62 | 10,214,383.71 | 1,617,907.9 |
| 其中:利息费用 | 10,945,223.03 | 39,739,279.77 | 28,115,663.07 | 17,868,283.95 |
| 其中:利息收入 | 2,409,858.79 | 11,125,515.61 | 8,324,746.77 | 4,581,339.55 |
| 加:投资收益 | -760,243.82 | 9,836,416.05 | 8,399,571.55 | 9,516,606.83 |
| 资产处置收益 | 1,760,884.21 | 1,419,533.61 | 1,201,542.62 | 1,240,258.42 |
| 资产减值损失(新) | - | -51,613,568.72 | -48,313,538.64 | -48,313,538.64 |
| 信用减值损失(新) | 100,000 | -9,462,280.63 | -8,073,501.52 | -8,193,415.41 |
| 其他收益 | 12,233,676.46 | 58,188,339.6 | 47,979,403.05 | 35,032,548.75 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 143,171,264.96 | 534,370,670.27 | 398,270,352.14 | 307,569,985.06 |
| 加:营业外收入 | 325,013.26 | 8,481,488.89 | 659,426.07 | 326,560.85 |
| 减:营业外支出 | 806,901.64 | 9,198,735.84 | 6,012,150.78 | 4,532,708.22 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 142,689,376.58 | 533,653,423.32 | 392,917,627.43 | 303,363,837.69 |
| 减:所得税费用 | 27,045,573.46 | 46,938,849.44 | 37,468,356.21 | 30,597,489.83 |
| 六、净利润 | 115,643,803.12 | 486,714,573.88 | 355,449,271.22 | 272,766,347.86 |
| 持续经营净利润 | 115,643,803.12 | 486,714,573.88 | 355,449,271.22 | 272,766,347.86 |
| 归属于母公司股东的净利润 | 112,095,257.24 | 470,023,746.08 | 344,079,950.67 | 265,404,417.68 |
| 少数股东损益 | 3,548,545.88 | 16,690,827.8 | 11,369,320.55 | 7,361,930.18 |
| (一)基本每股收益 | 0.15 | 0.69 | 0.5 | 0.39 |
| (二)稀释每股收益 | 0.15 | 0.68 | 0.5 | 0.38 |
| 八、其他综合收益 | -10,645,120.96 | 56,232,510.23 | 74,961,072.66 | 27,326,906.39 |
| 归属于母公司股东的其他综合收益 | -10,573,077.19 | 55,979,397.24 | 75,223,458.18 | 27,600,823.6 |
| 九、综合收益总额 | 104,998,682.16 | 542,947,084.11 | 430,410,343.88 | 300,093,254.25 |
| 归属于母公司股东的综合收益总额 | 101,522,180.05 | 526,003,143.32 | 419,303,408.85 | 293,005,241.28 |
| 归属于少数股东的综合收益总额 | 3,476,502.11 | 16,943,940.79 | 11,106,935.03 | 7,088,012.97 |
| 公告日期 | 2025-04-29 | 2025-03-31 | 2024-10-30 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |